PepGen Announces First Participant Dosed in a Phase 1 Clinical Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
April 06, 2022 08:00 ET
|
PepGen, Inc.
- Initiation of Phase 1 Study Marks PepGen’s Transition to a Clinical Stage Company - - This Phase 1 Healthy Normal Volunteer (HNV) Study will Evaluate Safety and Tolerability as the Primary...
PepGen Appoints Michelle Mellion, M.D., as Senior Vice President, Head of Clinical Development
April 05, 2022 08:00 ET
|
PepGen, Inc.
BOSTON, April 05, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company developing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular...
PepGen Continues to Build Leadership Team with Additions of Senior Vice President, Clinical Operations and Vice President, Toxicology
March 30, 2022 08:00 ET
|
PepGen, Inc.
BOSTON, March 30, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurologic...
PepGen Announces Approval by Health Canada of CTA to Begin First in Human Trials of PGN-EDO51 to Treat Duchenne Muscular Dystrophy
March 15, 2022 08:00 ET
|
PepGen, Inc.
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- PepGen Inc., a company advancing the next generation of oligonucleotide therapies for neuromuscular and neurologic diseases, today announced approval by...
PepGen Appoints Laurie Keating as Chair of Board of Directors
January 19, 2022 08:00 ET
|
PepGen, Inc.
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed...
PepGen Appoints Vice President of Program Management and Promotes Sonia Bracegirdle, Ph.D., to Senior Vice President, Strategy & Operations
December 07, 2021 08:00 ET
|
PepGen, Inc.
Dr. Bracegirdle to lead expanded PepGen Strategy and Operations teamIsami J. Salcedo, experienced biotechnology operations and program management professional, joins as Vice President of Program...
PepGen Bolsters R&D Team with Appointment of Jaya Goyal, Ph.D., as Executive Vice President of Research and Preclinical Development
November 08, 2021 08:00 ET
|
PepGen, Inc.
BOSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the addition of Jaya...
PepGen Appoints Noel Donnelly as Chief Financial Officer
October 28, 2021 08:00 ET
|
PepGen, Inc.
BOSTON, Oct. 28, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced that it has appointed...
PepGen Welcomes Esteemed Neurologist Dr. John Day to Scientific Advisory Board
October 13, 2021 08:00 ET
|
PepGen, Inc.
BOSTON, Oct. 13, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular and neurologic diseases, today announced the appointment of...
PepGen To Present Research on Enhanced Delivery Treatments for Neuromuscular Disease at Two Scientific Conferences in September
September 20, 2021 07:00 ET
|
PepGen, Inc.
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Chief Executive Officer James...